Charles River Laboratories International (CRL) Cost of Revenue (2009 - 2026)

Charles River Laboratories International has reported Cost of Revenue for 18 years, with the latest figure at $552.0 million in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 5.62% year-over-year to $552.0 million in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 6.66% increase from a year earlier, with the FY2025 full-year figure at $2.3 billion, down 1.32% from the prior year.
• Cost of Revenue was $552.0 million for Q2 2026 at Charles River Laboratories International, down from $608.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $672.4 million in Q2 2024, with the low at $318.5 million in Q4 2023.
• Average Cost of Revenue over 5 years is $570.0 million, with a median of $582.3 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue sank 47.19% in 2023, then jumped 67.62% in 2025.
• Over 5 years, Cost of Revenue stood at $603.1 million in 2022, then tumbled by 47.19% to $318.5 million in 2023, then grew by 8.6% to $345.9 million in 2024, then soared by 67.62% to $579.8 million in 2025, then fell by 4.8% to $552.0 million in 2026.
• The last three Cost of Revenue figures came in at $552.0 million (Q2 2026), $608.9 million (Q1 2026), and $579.8 million (Q4 2025), per Business Quant data.